The new company, which will further develop a plaster that can diagnose whether a patient is in risk of coronary thrombosis, is looking for investors in Denmark and abroad In Denmark 20% of all deaths are caused by cardiac arrest due to coronary thrombosis, a condition caused by coronary artery disease, which a newly founded company aims to help diagnose with a novel heart plaster that is under development. Acarix is the name of the new firm founded by Coloplast and Aalborg University, which respectively have a 37% and 27.5% shareholding, while the remaining shares are owned by Acarix's management and others who have invested in the technology